Evaluating medication titration patterns in response to first PTH 300–600 pg/ml, the investigators determined that patients who had more proactive treatment (e.g., upward titration of CKD-MBD medications) within 30 days of first PTH 300–600 pg/ml had lower rates of mortality and cardiovascular disease over 2 years. This evidence concerns the gene PTH and chronic kidney disease.